DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20214726
Published: 2021-11-26

Rheumatoid arthritis onset after COVID-19 infection: a case report

Thafar S. A. Safar, Karmen B. Katay, Reem H. Khamis

Abstract


At the end of 2019, coronavirus disease (COVID-19) outbreak is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Worldwide researchers and physician try to explore the mechanisms of damage induced by virus, they focus on the short-term and long-term immune-mediated consequences induced by the virus infection. Every day discover a new pathological condition induced by virus and new symptoms and disease may occur after recovery from disease. Our case report is 41 years old, Indian lady who presented to our primary health care centre complaining of multiple small hand joints pain, both elbows and knees pain with swelling of them and prolonged morning stiffness, diagnosed seropositive rheumatoid arthritis (RA) (arthritis, positive rheumatoid factor (RF), and X-ray changes) after 1 month recovery from COVID-19 infection. She did not have any joint pain and she had negative RF before COVID-19 infection with no family history of RA.


Keywords


Rheumatoid arthritis, COVID-19, Rheumatic factor, Polyarthritis, Corona infection

Full Text:

PDF

References


https://www.cdc.gov/coronavirus/2019-ncov/hcp/ambulatory-care-settings.html (Accessed on May , 20, 2021).

Vlachoyiannopoulos PG, Magira E, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis 2020;79:1661–3.

Borghi MO, Beltagy A, Garrafa E, et al. Anti-Phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunology 2020;11:58424

Perrot L, Hemon M, Busnel J-M, et al. First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Lancet Rheumatology 2021;3: e6–81.

Spiezia L, Simioni P, et al (2020) COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 120:998–1000. https://doi.org/ 10.1055/s-0040-1710018

Wichmann D, Sperhake JP, Kluge S, et al (2020) Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 173:268–277. https:// doi.org/10.7326/M20-2003

McGonagle D, Sharif K, O’Regan A et al (2020) The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmune Rev 19:102537. https://doi.org/10.1016/j.autrev.2020.102537

Henderson LA, Canna SW, et al (2020) On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheum 72:1059–1063. https://doi.org/10.1002/art.41285

Jones VG, Mills M, Suarez D, et al (2020) COVID19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 10:537–540. https://doi.org/10.1542/hpeds.2020-0123

Viner RM, Whittaker E (2020) Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet 395:1741– 1743. https://doi.org/10.1016/S0140-6736(20)31129-6

Aletaha D, Neogi T, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.

Pincus T, Callahan LF. How many types of patients meet classification criteria for rheumatoid arthritis? J Rheumatology 1994; 21:1385.

Parisi P, Borrelli R, et al. Viral arthritis and COVID-19. Lancet Rheumatol 2020; 2: e655–67.

Najafi S, Rajaei E, et al.. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. Clin Rheumatol 2020; 39: 3223–35

Hiroyuki Fujii H, et al. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review. Clin Rheumatol 2020; 39: 3171–75.